[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100397498":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":22,"responsibleParty":39,"collaborators":43,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":7,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Boston Children's Hospital","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Wanda Phipatanakul, MD. MS.","PRINCIPAL_INVESTIGATOR",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Rachel Dabek, MD. MPH.","CONTACT","857-218-5336","asthma@childrens.harvad.edu",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Hannah Foster","857-218-3819","asthma@childrens.harvard.edu",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-71.05977,42.35843,{"lat":34,"lon":33},[37],{"name":38,"role":15,"phone":16,"phoneExt":7,"email":21},"Amparito Cunningham",{"type":11,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":42,"oldNameTitle":7,"oldOrganization":7},"Wanda Phipatanakul","Professor of Pediatrics, Director Asthma Research Center","Harvard Medical School (HMS and HSDM)",[44],{"name":45,"class":46},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100397498","mechanisms-of-increased-disease-severity-in-ad-patients-with-the-il-4ra-r576-polymorphism-100397498",false,"NCT04455906","Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism","Inclusion Criteria:\n\n1. Male or female participants ≥6 to 65 yrs of age\n2. Meet AD Standard Diagnostic Criteria\n\nExclusion Criteria:\n\n1. Enrollment in another clinical trial\n2. Hypersensitivity to an agent used for the skin decolonization protocol\n3. Use within 4 weeks of systemic treatment with immunosuppressive\u002Fimmunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)\n4. Phototherapy for AD within 4 weeks\n5. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks\n6. Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days\n7. Bleach baths within 7 days of the first Visit\n8. Use of oral or topical antibiotics within 21 days of the beginning of the study\n9. Asthmatics receiving more than 500 μg per day of inhaled corticosteroids\n10. History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy\n11. Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,\n12. Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.\n13. Febrile illness at time of visits\n14. Suspected immune deficiency or family history of primary immunodeficiency","ALL","6 Years","65 Years",{"count":57,"type":58},111,"ESTIMATED","OBSERVATIONAL","This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.",[62],"Atopic Dermatitis","2026-05-15",{"date":65,"type":66},"2026-05-18","ACTUAL",{"date":68,"type":66},"2020-11-30",{"date":70,"type":58},"2027-09-15",{"name":5,"class":6},1]